Latest Regulatory News

MAC Copper Limited has scheduled a key court hearing on July 30 to progress Harmony Gold’s recommended acquisition, moving closer to shareholder votes and regulatory approvals.

Invex Therapeutics has broadened its collaboration with Tessara Therapeutics to explore Exenatide’s potential in Alzheimer’s disease, while successfully renewing key orphan drug designations in Europe and the US.

Hutchison Telecommunications (Australia) Limited has been suspended from ASX trading following compulsory acquisition notices issued by its Amsterdam-based parent company.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase to $204 million in Q2 2025, launched its new prostate cancer imaging agent Gozellix in the U.S., and advanced key clinical trials despite an ongoing SEC inquiry.

Adherium Limited has appointed seasoned medtech executive Dawn Bitz as CEO to spearhead the expansion of its Hailie® respiratory monitoring platform, with a strong focus on the US market.

The Supreme Court of Western Australia has approved the scheme of arrangement for Ramelius Resources to acquire Spartan Resources, marking a significant consolidation in the gold mining sector.

Nico Resources Limited reported steady progress on its Wingellina nickel-cobalt project despite challenging market conditions, completing a $1.1 million share placement and advancing metallurgical and drilling programs.

Prodigy Gold NL has lodged a replacement Appendix 3Y to amend the reported securities held by Managing Director Mark Edwards following his participation in the company’s recent Entitlement Offer.

Kingsland Minerals has withdrawn its previously implied production target for the Leliyn Graphite Project’s processing plant, citing non-compliance with ASX disclosure rules and advising investors to disregard prior estimates.

Inhalerx Limited has drawn $247,000 from a $38.5 million funding facility to advance clinical trials for its IRX-211 and IRX-616a drug candidates, reporting positive operating cash flow for the quarter ending June 2025.

InhaleRx Limited has secured key ethics approvals and initiated manufacturing for its inhaled drug candidates targeting breakthrough cancer pain and panic disorder, supported by a $38.5 million funding facility to accelerate development.

Alternative Investment Trust (ASX, AIQ) announces a special unfranked distribution of AUD 0.04647 per unit, representing a full return of capital payable in early August.